Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of Angelica sinensis (commonly known as Dong quai or Chinese angelica) and Porphyridium (a genus of red microalgae). Angelica sinensis is a traditional Chinese medicinal herb widely used for its purported effects on blood health, immune modulation, anti-inflammatory activity, antioxidation, hepatoprotection, antifibrosis, hypoglycemia, antitumor activity, and more. Its main active components include polysaccharides that have demonstrated broad pharmacological activities in preclinical studies[5][6]. Porphyridium is primarily known for its bioactive compounds such as sulfated polysaccharides with antioxidant and immunomodulatory properties; however, there are no well-documented pharmaceutical products or clinical trials specifically combining these two ingredients. The combination would be considered a multi-ingredient dietary supplement rather than an approved pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on angelica sinensis + porphyridium.